A Safety Study of NNZ-2566 in Patients With Rett Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Rett Syndrome
Interventions
DRUG

NNZ-2566

Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.

DRUG

Placebo

Strawberry flavored solution and Water for Injection

Trial Locations (3)

55101

Gillette Children's Specialty Healthcare, Saint Paul

77030

Baylor School of Medicine, Houston

35294-0113

University of Alabama, Birmingham

Sponsors
All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

collaborator

International Rett Syndrome Foundation

OTHER

lead

Neuren Pharmaceuticals Limited

INDUSTRY

NCT01703533 - A Safety Study of NNZ-2566 in Patients With Rett Syndrome | Biotech Hunter | Biotech Hunter